BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 20478527)

  • 1. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
    Yu J; Yu J; Mani RS; Cao Q; Brenner CJ; Cao X; Wang X; Wu L; Li J; Hu M; Gong Y; Cheng H; Laxman B; Vellaichamy A; Shankar S; Li Y; Dhanasekaran SM; Morey R; Barrette T; Lonigro RJ; Tomlins SA; Varambally S; Qin ZS; Chinnaiyan AM
    Cancer Cell; 2010 May; 17(5):443-54. PubMed ID: 20478527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
    Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
    Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
    Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
    Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
    Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
    Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.
    Börno ST; Fischer A; Kerick M; Fälth M; Laible M; Brase JC; Kuner R; Dahl A; Grimm C; Sayanjali B; Isau M; Röhr C; Wunderlich A; Timmermann B; Claus R; Plass C; Graefen M; Simon R; Demichelis F; Rubin MA; Sauter G; Schlomm T; Sültmann H; Lehrach H; Schweiger MR
    Cancer Discov; 2012 Nov; 2(11):1024-35. PubMed ID: 22930729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
    Goel S; Bhatia V; Kundu S; Biswas T; Carskadon S; Gupta N; Asim M; Morrissey C; Palanisamy N; Ateeq B
    Nat Commun; 2021 Sep; 12(1):5325. PubMed ID: 34493733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
    Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
    PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation between Polycomb and androgen receptor during oncogenic transformation.
    Zhao JC; Yu J; Runkle C; Wu L; Hu M; Wu D; Liu JS; Wang Q; Qin ZS; Yu J
    Genome Res; 2012 Feb; 22(2):322-31. PubMed ID: 22179855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
    Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
    Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers.
    Alumkal JJ; Herman JG
    Cancer Discov; 2012 Nov; 2(11):979-81. PubMed ID: 23148372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.
    Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A
    BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.
    Ma T; Jin L; Bai S; Liu Z; Wang S; Shen B; Cho Y; Cao S; Sun MJS; Fazli L; Zhang D; Wedderburn C; Zhang DY; Mugon G; Ungerleider N; Baddoo M; Zhang K; Schiavone LH; Burkhardt BR; Fan J; You Z; Flemington EK; Dong X; Dong Y
    J Natl Cancer Inst; 2024 Mar; 116(3):421-433. PubMed ID: 37847647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
    Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
    Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
    Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    Linn DE; Bronson RT; Li Z
    PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.
    Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q
    Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.
    Kedage V; Strittmatter BG; Dausinas PB; Hollenhorst PC
    J Biol Chem; 2017 Oct; 292(42):17225-17235. PubMed ID: 28887309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.